Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adicet Bio, Inc.ACET · Entity 6860 | Director | June 21, 2026 | June 23, 2026 |
| Praxis Precision Medicines, Inc.PRAX · Entity 3538 | Director | June 10, 2026 | June 12, 2026 |
| Schrodinger, Inc.SDGR · Entity 4667 | Director | June 22, 2026 | June 23, 2026 |
| TETRAPHASE PHARMACEUTICALS INCTTPH · Entity 147285 | Director | June 10, 2019 | June 11, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adicet Bio, Inc.
Report date June 21, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.10 · Expires 2036-06-20 | Direct | 4,200 |
Reported balance
After 2026-06-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-21 · Grant · Acquired 4,200 · Balance 4,200 F1: These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.
Praxis Precision Medicines, Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,371 |
Reported balance
After 2026-06-10 transaction · row 1
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 1,371 · Balance 1,371 F1: Dr. Chodakewitz was awarded 1,371 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $240.66 · Expires 2036-06-10 | Direct | 648 |
Reported balance
After 2026-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-10 · Grant · Acquired 648 · Balance 648 F2: The shares subject to this option shall vest in twelve (12) equal monthly installments occurring on the 10th day of each month, with the first such installment occurring on July 10, 2026 and the final such installment occurring on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Dr. Chodakewitz was awarded 1,371 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
F2: The shares subject to this option shall vest in twelve (12) equal monthly installments occurring on the 10th day of each month, with the first such installment occurring on July 10, 2026 and the final such installment occurring on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders.
Schrodinger, Inc.
Report date June 22, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,388 |
Reported balance
After 2026-06-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-22 · Grant · Acquired 8,141 · Balance 25,388 F1: Grant of restricted stock units ("RSUs") under the Issuer's 2022 Equity Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs were granted on June 22, 2026 and shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service. The settlement of such RSUs will be deferred until the earlier of (i) the 30th day following the reporting person's separation from service from the Issuer or (ii) certain change in control events. F2: Includes 8,141 unvested RSUs. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.23 · Expires 2036-06-22 | Direct | 13,313 |
Reported balance
After 2026-06-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-22 · Grant · Acquired 13,313 · Balance 13,313 F3: The option was granted on June 22, 2026 under the Issuer's 2022 Equity Incentive Plan, as amended. The award shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units ("RSUs") under the Issuer's 2022 Equity Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs were granted on June 22, 2026 and shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service. The settlement of such RSUs will be deferred until the earlier of (i) the 30th day following the reporting person's separation from service from the Issuer or (ii) certain change in control events.
F2: Includes 8,141 unvested RSUs.
F3: The option was granted on June 22, 2026 under the Issuer's 2022 Equity Incentive Plan, as amended. The award shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service.
TETRAPHASE PHARMACEUTICALS INC
Report date June 10, 2019 · Filed June 11, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.77 · Expires 2029-06-09 | Direct | 16,500 |
Reported balance
After 2019-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-10 · Grant · Acquired 16,500 · Balance 16,500 F1: Vests in equal quarterly installments over a one-year period measured from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Vests in equal quarterly installments over a one-year period measured from the date of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
VERTEX PHARMACEUTICALS INC / MA
Report date April 01, 2018 · Filed April 02, 2018
Section 16 reporting ended · disclosed 2018-04-02. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 12, 2018 Filed Feb 14, 2018 23:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 400 | $152.62 | $61,048.00 |
DisclosureSEC source: 0001209191-18-010119 · doc4.xml · nonDerivative · entry 4 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,963 F1 · kind: Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1. F3 · price: Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $152.62 (range $152.09 to $152.96). Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 23:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,022 | $151.26 | $305,847.72 |
DisclosureSEC source: 0001209191-18-010119 · doc4.xml · nonDerivative · entry 3 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,363 F1 · kind: Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1. F3 · price: Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $151.26 (range $150.88 to $151.86). Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 23:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,100 | $150.47 | $165,517.00 |
DisclosureSEC source: 0001209191-18-010119 · doc4.xml · nonDerivative · entry 2 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,385 F1 · kind: Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1. F3 · price: Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $150.47 (range $149.83 to $150.76). Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 23:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,300 | $149.21 | $193,973.00 |
DisclosureSEC source: 0001209191-18-010119 · doc4.xml · nonDerivative · entry 1 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,485 F1 · kind: Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $149.21 (range $148.80 to $149.64). F3 · price: Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 22:49 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 23,479 | $0.00 Strike: $155.57 | $0.00 |
DisclosureSEC source: 0001209191-18-008515 · doc4.xml · derivative · entry 3 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,479 Underlying: Common Stock · 23,479 shares Expires 2028-02-05 F3 · derivative.exercise_date: This option vests in 16 quarterly installments from 2/6/2018. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 22:49 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 10,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008515 · doc4.xml · nonDerivative · entry 2 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,785 F2 · shares: Restricted stock unit award that vests in three equal installments on 2/17/2019, 2/17/2020 and 2/17/2021. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 22:49 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 12,136 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008515 · doc4.xml · nonDerivative · entry 1 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,660 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 2/3/2017 that contained both performance-vesting and service-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 2/6/2018. The earned performance shares remain subject to the service-vesting requirements and will vest in three equal installments on 2/10/2018, 2/10/2019 and 2/10/2020. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,594 | $0.00 Strike: $109.14 | $0.00 |
DisclosureSEC source: 0001209191-18-008224 · doc4.xml · derivative · entry 9 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,375 Underlying: Common Stock · 3,594 shares Expires 2025-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/3/2015. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $164.71 | $16,471.00 |
DisclosureSEC source: 0001209191-18-008224 · doc4.xml · nonDerivative · entry 8 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,524 F1 · kind: Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 900 | $164.12 | $147,708.00 |
DisclosureSEC source: 0001209191-18-008224 · doc4.xml · nonDerivative · entry 7 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,624 F1 · kind: Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1. F1 · price: Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1. F8 · price: Open market sales reported on this line occurred at a weighted average price of $164.12 (range $163.65 to $164.53). Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 400 | $162.94 | $65,176.00 |
DisclosureSEC source: 0001209191-18-008224 · doc4.xml · nonDerivative · entry 6 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,524 F1 · kind: Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1. F1 · price: Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1. F7 · price: Open market sales reported on this line occurred at a weighted average price of $162.94 (range $162.52 to $163.40). Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 500 | $161.51 | $80,755.00 |
DisclosureSEC source: 0001209191-18-008224 · doc4.xml · nonDerivative · entry 5 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,924 F1 · kind: Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1. F3 · price: Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $161.51 (range $161.32 to $161.85). Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 500 | $160.50 | $80,250.00 |
DisclosureSEC source: 0001209191-18-008224 · doc4.xml · nonDerivative · entry 4 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,424 F1 · kind: Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1. F3 · price: Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $160.50 (range $160.20 to $160.86). Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 700 | $159.62 | $111,734.00 |
DisclosureSEC source: 0001209191-18-008224 · doc4.xml · nonDerivative · entry 3 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,924 F1 · kind: Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1. F3 · price: Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $159.62 (range $159.18 to $160.06). Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 494 | $158.32 | $78,210.08 |
DisclosureSEC source: 0001209191-18-008224 · doc4.xml · nonDerivative · entry 2 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,624 F1 · kind: Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $158.32 (range $158.01 to $158.82). F3 · price: Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 3,594 | $109.14 | $392,249.16 |
DisclosureSEC source: 0001209191-18-008224 · doc4.xml · nonDerivative · entry 1 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,118 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2018 Filed Feb 5, 2018 22:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,796 | $0.00 Strike: $91.05 | $0.00 |
DisclosureSEC source: 0001209191-18-007617 · doc4.xml · derivative · entry 7 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,368 Underlying: Common Stock · 1,796 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/2/2016. Read SEC document |
| February 02, 2018 Filed Feb 5, 2018 22:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $169.49 | $16,949.00 |
DisclosureSEC source: 0001209191-18-007617 · doc4.xml · nonDerivative · entry 6 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,524 F1 · kind: Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1. Read SEC document |
| February 02, 2018 Filed Feb 5, 2018 22:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $168.06 | $16,806.00 |
DisclosureSEC source: 0001209191-18-007617 · doc4.xml · nonDerivative · entry 5 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,624 F1 · kind: Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1. Read SEC document |
| February 02, 2018 Filed Feb 5, 2018 22:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 996 | $166.10 | $165,435.60 |
DisclosureSEC source: 0001209191-18-007617 · doc4.xml · nonDerivative · entry 4 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,724 F1 · kind: Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1. F3 · price: Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $166.10 (range $165.81 to $166.43). Read SEC document |
| February 02, 2018 Filed Feb 5, 2018 22:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 600 | $165.23 | $99,138.00 |
DisclosureSEC source: 0001209191-18-007617 · doc4.xml · nonDerivative · entry 3 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,720 F1 · kind: Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $165.23 (range $164.80 to $165.67). F3 · price: Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 02, 2018 Filed Feb 5, 2018 22:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,796 | $91.05 | $163,525.80 |
DisclosureSEC source: 0001209191-18-007617 · doc4.xml · nonDerivative · entry 2 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,320 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 22:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,900 | $167.44 | $318,136.00 |
DisclosureSEC source: 0001209191-18-007617 · doc4.xml · nonDerivative · entry 1 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,524 F1 · kind: Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1. Read SEC document |
| January 16, 2018 Filed Jan 17, 2018 21:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,719 | $0.00 Strike: $96.87 | $0.00 |
DisclosureSEC source: 0001209191-18-003958 · doc4.xml · derivative · entry 5 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,438 Underlying: Common Stock · 1,719 shares Expires 2024-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests in 16 quarterly installments from 7/15/2014. Read SEC document |
| January 16, 2018 Filed Jan 17, 2018 21:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $159.04 | $47,712.00 |
DisclosureSEC source: 0001209191-18-003958 · doc4.xml · nonDerivative · entry 4 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,424 F1 · kind: Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1. Read SEC document |
| January 16, 2018 Filed Jan 17, 2018 21:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 900 | $157.54 | $141,786.00 |
DisclosureSEC source: 0001209191-18-003958 · doc4.xml · nonDerivative · entry 3 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,724 F1 · kind: Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1. F3 · price: Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $157.54 (range $156.95 to $157.83). Read SEC document |
| January 16, 2018 Filed Jan 17, 2018 21:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 519 | $155.80 | $80,860.20 |
DisclosureSEC source: 0001209191-18-003958 · doc4.xml · nonDerivative · entry 2 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,624 F1 · kind: Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $155.80 (range $155.77 to $155.91). F3 · price: Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| January 16, 2018 Filed Jan 17, 2018 21:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,719 | $96.87 | $166,519.53 |
DisclosureSEC source: 0001209191-18-003958 · doc4.xml · nonDerivative · entry 1 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,143 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,438 | $0.00 Strike: $73.51 | $0.00 |
DisclosureSEC source: 0001209191-18-001000 · doc4.xml · derivative · entry 6 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,438 shares Expires 2024-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 863 | $152.80 | $131,866.40 |
DisclosureSEC source: 0001209191-18-001000 · doc4.xml · nonDerivative · entry 5 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,424 F1 · kind: Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1. F3 · price: Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $152.80 (range $152.70 to $153.03). Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,600 | $152.06 | $243,296.00 |
DisclosureSEC source: 0001209191-18-001000 · doc4.xml · nonDerivative · entry 4 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,287 F1 · kind: Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1. F3 · price: Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $152.06 (range $151.70 to $152.69). Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 675 | $150.87 | $101,837.25 |
DisclosureSEC source: 0001209191-18-001000 · doc4.xml · nonDerivative · entry 3 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,887 F1 · kind: Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1. F3 · price: Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $150.87 (range $150.53 to $151.50). Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $149.65 | $44,895.00 |
DisclosureSEC source: 0001209191-18-001000 · doc4.xml · nonDerivative · entry 2 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,562 F1 · kind: Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $149.65 (range $149.41 to $149.92). F3 · price: Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 3,438 | $73.51 | $252,727.38 |
DisclosureSEC source: 0001209191-18-001000 · doc4.xml · nonDerivative · entry 1 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,862 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2017 Filed Nov 6, 2017 22:50 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,594 | $0.00 Strike: $109.14 | $0.00 |
DisclosureSEC source: 0001209191-17-059474 · doc4.xml · derivative · entry 8 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,969 Underlying: Common Stock · 3,594 shares Expires 2025-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/3/2015. Read SEC document |
| November 03, 2017 Filed Nov 6, 2017 22:50 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,594 | $144.69 | $520,015.86 |
DisclosureSEC source: 0001209191-17-059474 · doc4.xml · nonDerivative · entry 6 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,424 F1 · kind: Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1. F3 · price: Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $144.69 (range $144.19 to $144.90). Read SEC document |
| November 03, 2017 Filed Nov 6, 2017 22:50 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 3,594 | $109.14 | $392,249.16 |
DisclosureSEC source: 0001209191-17-059474 · doc4.xml · nonDerivative · entry 5 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 22:50 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,796 | $0.00 Strike: $91.05 | $0.00 |
DisclosureSEC source: 0001209191-17-059474 · doc4.xml · derivative · entry 7 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,164 Underlying: Common Stock · 1,796 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/2/2016. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 22:50 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $145.89 | $43,767.00 |
DisclosureSEC source: 0001209191-17-059474 · doc4.xml · nonDerivative · entry 4 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,424 F1 · kind: Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1. F3 · price: Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $145.89 (range $145.63 to $146.04). Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 22:50 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,096 | $144.89 | $158,799.44 |
DisclosureSEC source: 0001209191-17-059474 · doc4.xml · nonDerivative · entry 3 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,724 F1 · kind: Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1. F3 · price: Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $144.89 (range $144.48 to $145.18). Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 22:50 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 400 | $143.54 | $57,416.00 |
DisclosureSEC source: 0001209191-17-059474 · doc4.xml · nonDerivative · entry 2 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,820 F1 · kind: Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $143.54 (range $142.98 to $143.81). F3 · price: Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 22:50 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,796 | $91.05 | $163,525.80 |
DisclosureSEC source: 0001209191-17-059474 · doc4.xml · nonDerivative · entry 1 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,220 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 31, 2017 Filed Oct 31, 2017 22:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $149.34 | $29,868.00 |
DisclosureSEC source: 0001209191-17-058479 · doc4.xml · nonDerivative · entry 8 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,424 F1 · kind: Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1. Read SEC document |
| October 31, 2017 Filed Oct 31, 2017 22:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,400 | $148.40 | $207,760.00 |
DisclosureSEC source: 0001209191-17-058479 · doc4.xml · nonDerivative · entry 7 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,624 F1 · kind: Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1. F3 · price: Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9 · price: Open market sales reported on this line occurred at a weighted average price of $148.40 (range $148.19 to $148.70). Read SEC document |
| October 31, 2017 Filed Oct 31, 2017 22:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,400 | $147.75 | $502,350.00 |
DisclosureSEC source: 0001209191-17-058479 · doc4.xml · nonDerivative · entry 6 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,024 F1 · kind: Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1. F3 · price: Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $147.75 (range $147.18 to $148.15). Read SEC document |
| October 31, 2017 Filed Oct 31, 2017 22:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,700 | $146.52 | $688,644.00 |
DisclosureSEC source: 0001209191-17-058479 · doc4.xml · nonDerivative · entry 5 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,424 F1 · kind: Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1. F3 · price: Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $146.52 (range $146.16 to $147.14). Read SEC document |
| October 31, 2017 Filed Oct 31, 2017 22:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 19,016 | $145.26 | $2,762,264.16 |
DisclosureSEC source: 0001209191-17-058479 · doc4.xml · nonDerivative · entry 4 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,124 F1 · kind: Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1. F3 · price: Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $145.26 (range $144.91 to $145.87). Read SEC document |
| October 31, 2017 Filed Oct 31, 2017 22:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 25,784 | $144.46 | $3,724,756.64 |
DisclosureSEC source: 0001209191-17-058479 · doc4.xml · nonDerivative · entry 3 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,140 F1 · kind: Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1. F3 · price: Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $144.46 (range $143.90 to $144.89). Read SEC document |
| October 31, 2017 Filed Oct 31, 2017 22:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,100 | $143.46 | $588,186.00 |
DisclosureSEC source: 0001209191-17-058479 · doc4.xml · nonDerivative · entry 2 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,924 F1 · kind: Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1. F3 · price: Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $143.46 (range $142.87 to $143.85). Read SEC document |
| October 31, 2017 Filed Oct 31, 2017 22:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,400 | $142.38 | $199,332.00 |
DisclosureSEC source: 0001209191-17-058479 · doc4.xml · nonDerivative · entry 1 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,024 F1 · kind: Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $142.38 (range $141.83 to $142.81). F3 · price: Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.